Compare Targa Resources Inc. Common Stock (TRGP) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

TRGP trades at $293.04, up 0.86% today, with a bullish technical signal driven by moving averages and a consensus analyst price target of $329.54. The company reported strong Q2 2026 EPS of $3.54, beating expectations, and maintains robust profitability with a net income margin of 13.54% and ROE of 72.27%. Recent news highlights a $1.25 quarterly dividend and sustainability reporting, reflecting stable operations.

The outlook is positive given earnings beats, high analyst buy ratings (82%), and projected revenue growth, though risks include commodity price exposure and high debt-to-asset ratio of 68.07%. The stock's current price near the analyst low target of $294.00 suggests potential upside if fundamentals hold.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.